| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SRRA | Common Stock | Disposed to Issuer | -$150M | -2.74M | -100% | $55.00 | 0 | Jul 1, 2022 | By: Vivo Opportunity Fund Holdings, L.P. | F1, F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SRRA | Stock Option (right to buy) | Disposed to Issuer | $0 | -1.5K | -100% | $0.00* | 0 | Jul 1, 2022 | Common Stock | 1.5K | $13.87 | Direct | F3, F4 |
| transaction | SRRA | Stock Option (right to buy) | Disposed to Issuer | $0 | -6.87K | -100% | $0.00* | 0 | Jul 1, 2022 | Common Stock | 6.87K | $13.98 | Direct | F4, F5 |
| transaction | SRRA | Stock Option (right to buy) | Disposed to Issuer | $0 | -6K | -100% | $0.00* | 0 | Jul 1, 2022 | Common Stock | 6K | $18.11 | Direct | F4, F6 |
| transaction | SRRA | Series A Warrant | Disposed to Issuer | $0 | -1.46M | -100% | $0.00* | 0 | Jul 1, 2022 | Common Stock | 1.46M | $13.20 | By: Vivo Opportunity Fund Holdings, L.P. | F2, F7 |
Gaurav Aggarwal is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
| Id | Content |
|---|---|
| F1 | Pursuant to an Agreement and Plan of Merger, dated April 12, 2022, between GlaxoSmithKline plc ("GSK"), Orikum Acquisition Inc. ("Merger Sub") and the Issuer (the "Merger Agreement"), Merger Sub merged with and into the Issuer on July 1, 2022, with the Issuer surviving as a wholly-owned subsidiary of GSK (the "Merger"). At the effective time of the Merger, each outstanding share of common stock of the Issuer automatically and without any required action on the part of the Reporting Person, was converted into the right to receive $55.00 in cash, without interest. |
| F2 | Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P., the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| F3 | The option fully vested on November 29, 2020. |
| F4 | At the effective time of the Merger, each stock option outstanding, whether vested or unvested, automatically and without any required action on the part of the Reporting Person, was cancelled in exchange for the right to receive an amount in cash equal to the excess, if any, of $55.00 over the per share exercise price of such stock option. |
| F5 | The option fully vested on June 9, 2021. |
| F6 | The option fully vested on June 8, 2022. |
| F7 | Pursuant to the terms of the Merger Agreement, the Issuer's outstanding Series A Warrants (the "Series A Warrants") were treated in accordance with their respective terms such that, at the effective time of the Merger, the outstanding Series A Warrants were cancelled and thereafter represent only the right to receive an amount in cash, without interest, equal to the Black Scholes Value (as defined in the Series A Warrants), which as calculated under the terms of the Series A Warrants equaled $45.98 per share of common stock underlying such warrants. |